Generate Biomedicines
Clinical trials sponsored by Generate Biomedicines, explained in plain language.
-
New asthma drug could cut attacks with just two shots a year
Disease control Recruiting nowThis phase 3 trial tests whether GB-0895, given every 6 months, can reduce asthma attacks in adults and teens (ages 12–80) with severe asthma that isn't controlled by standard inhalers. About 786 participants will receive either GB-0895 or a placebo, and researchers will track ho…
Phase: PHASE3 • Sponsor: Generate Biomedicines • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New shot every 6 months could slash severe asthma attacks
Disease control Recruiting nowThis study tests a new medicine called GB-0895 for people aged 12 to 80 with severe asthma that is not controlled by standard inhalers. Participants receive either GB-0895 or a placebo as a shot every 6 months for a year. The goal is to see if GB-0895 can reduce the number of ser…
Phase: PHASE3 • Sponsor: Generate Biomedicines • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo aims to tame Chemo's nerve damage in bladder cancer
Symptom relief Recruiting nowThis early-phase study tests an investigational drug called GB-4362 given alongside standard treatments (enfortumab vedotin and pembrolizumab) for adults with advanced or metastatic urothelial cancer. The goal is to see if GB-4362 can safely neutralize a chemotherapy byproduct th…
Phase: PHASE1 • Sponsor: Generate Biomedicines • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC